Olaparib, PARP1 inhibitor in ovarian cancer

Expert Opinion on Investigational Drugs

Volumn 21, Issue 10, 2012, Pages 1575-1584

  Marchetti, Claudia ^a   Imperiale, Ludovica ^a   Gasparri, Maria Luisa ^a   Palaia, Innocenza ^a   Pignata, Sandro ^b   Boni, Terenzio ^a   Bellati, Filippo ^a   Benedetti Panici, Pierluigi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

BRCA1 2; Ovarian cancer; Polyadenosine diphosphate ribose polymerase inhibitors; Target therapy

Indexed keywords

BEVACIZUMAB; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; DACARBAZINE; DOXORUBICIN; GEMCITABINE; IRINOTECAN; OLAPARIB; PACLITAXEL; POLY(ADENOSINE DIPHOSPHATE RIBOSE); RUCAPARIB; TOPOTECAN; VELIPARIB;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ASTHENIA; BACKACHE; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CELL STRAIN MCF 7; DIARRHEA; DNA REPAIR; DRUG ABSORPTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MEDLINE; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR CELL; UTERINE TUBE CARCINOMA; VOMITING;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84866531335     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.707189     Document Type: Review

References (41)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
2. Erratum, CA Cancer J Clin 2011;61:134
3. Dinh P, Harnett P, Piccart-Gebhart MJ, et al. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol 2008;67:103-12
4. Heintz A, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J Gynaecol Obstet 2006;95(Suppl 1):S161-92
5. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009;114(1):26-31
6. Szabo C, Zingarelli B, O'Connor M, et al. DNA strand breakage, activation of poly(ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci USA 1996;93:1753-8 (Pubitemid 26079829)
7. de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997;94:7303-7 (Pubitemid 27345310)
8. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434(7035):913-17 (Pubitemid 40559005)
9. Pecorelli S, Favalli G, Gadducci A, et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol 2009;27(28):4642-8
10. Markman M. Why study third-, fourth-, fifth-, line chemotherapy of ovarian cancer? Gynecol Oncol 2001;83(3):449-50 (Pubitemid 33139701)
11. Mukhopadhyay A, Elattar A, Cerbinskaite A, et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumour and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 2010;16(8):2344-51
12. Menear KA, Adcock C, Boulter R, et al. 4-[3-(4- cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008;51(20):6581-91
13. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumours from BRCA mutation carriers. N Engl J Med 2009;361:123-34
14. Sessa C. Update on PARP1 inhibitors in ovarian cancer. Ann Oncol 2011;22(Suppl 8):S72-6
15. Fong PC, Yap TA, Boss DS, et al. Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-19
16. Yamamoto N, Nokihara H, Yamada Y, et al. A phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumours. Cancer Sci 2012;103(3):504-9
17. Palma JP, Rodriguez LE, Bontcheva-Diaz VD, et al. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 2008;28(5A):2625-35
18. Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumour models. Clin Cancer Res 2007;13(9):2728-37 (Pubitemid 46795129)
19. Carden CP, Yap TA, Kaye SB. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Curr Opin Oncol 2010;22(5):473-80
20. Samol J, Ranson M, Scott E, et al. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, Olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumours: a phase I study. Invest New Drugs 2011;30(4):1493-500
21. Khan OA, Gore M, Lorigan P, et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 2011;104:750-5
22. Dent RA, Lindeman GJ, Clemons M, et al. Safety and efficacy of the oral PARP inhibitor Olaparib (AZD2281) in combination with paclitaxel for the first-or second-line treatment of patients with metastatic triple-negative breast cancer: results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol 2011;28(15S):abstract 1018
23. Rajan A, Carter CA, Kelly RJ, et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumours. Clin Cancer Res 2012;18(8):2344-51
24. Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 2000;460(1):1-15 (Pubitemid 30365046)
25. Rajan A, Carter CA, Kelly RJ, et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012;18(8):2344-51
26. Dean E, Middleton MR, Pwint T, et al. Phase I study to assess the safety and tolerability of Olaparib in combination with Bevacizumab in patients with advanced solid tumours. Br J Cancer 2012;106(3):468-74
27. Chan N, Bristow RG. Contextual" synthetic lethality and/or loss of heterozygosity: tumour hypoxia and modification of DNA repair. Clin Cancer Res 2010;16:4553-60
28. Martinek I, Haldar K, Gaitskell K, et al. DNA-repair pathway inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev 2010(6):CD007929
29. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376(9737):245-51
30. Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012;30(4):372-9
31. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19(14):3312-22 (Pubitemid 32642183)
32. Adams SF, Marsh EB, Elmasri W, et al. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol 2011;123(3):486-91
33. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet 2011;12:852-61
34. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012
35. Banerjee S, Kaye S. The role of targeted therapy in ovarian cancer. Eur J Cancer 2011;47(Suppl 3):S116-30
36. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010;28(22):3555-61
37. Banerjee S, Kaye S. PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr Oncol Rep 2011;13(6):442-9
38. Lee SA, Roques C, Magwood AC, et al. Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-type Rad51 expression. DNA Repair (Amst) 2009;9:170-81
39. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12 (Pubitemid 20213250)
40. Ang J, Yap TA, Fong P, et al. Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC). J Clin Oncol 2010;28(15s Suppl):abstract 5041
41. Norquist B, Wurz KA, Pennil CC, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011;29:3008-15